The complex role of NRF2 in cancer: A genomic view

Current Opinion in Toxicology

Volumn 1, Issue , 2016, Pages 37-45

  Praslicka, Brandon John ^a   Kerins, Michael John ^a   Ooi, Aikseng ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cancer; CUL3; KEAP1; NRF2; Somatic mutations

Indexed keywords

FUMARYLACETOACETASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; NOTCH RECEPTOR; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE E3;

CHEMORADIOTHERAPY; CHROMATIN IMMUNOPRECIPITATION; DNA SEQUENCE; GENE ACTIVATION; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; NEOPLASM; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; REVIEW; SOMATIC MUTATION; TUMOR DIFFERENTIATION; UPREGULATION;

EID: 85016782538     PISSN: None     EISSN: 24682020     Source Type: Journal    
DOI: 10.1016/j.cotox.2016.09.003     Document Type: Review

References (65)

1. 1 Simonis, E.J.A.A.A.M., General principles of nutritional toxicology, vol. 1, 1982, Academic Press Inc, London.
2. 2 Itoh, K., Mimura, J., Yamamoto, M., Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 13:11 (2010), 1665–1678.
3. 3 Lee, J., Godon, C., Lagniel, G., Spector, D., Garin, J., Labarre, J., et al. Yap1 and Skn7 control two specialized oxidative stress response regulons in yeast. J Biol Chem 274:23 (1999), 16040–16046.
4. 4 An, J.H., Vranas, K., Lucke, M., Inoue, H., Hisamoto, N., Matsumoto, K., et al. Regulation of the caenorhabditis elegans oxidative stress defense protein Skn-1 by glycogen synthase kinase-3. Proc Natl Acad Sci U S A 102:45 (2005), 16275–16280.
5. 5 Niu, W., Li, Z., Zhan, W., Iyer, V.R., Marcotte, E.M., Mechanisms of cell cycle control revealed by a systematic and quantitative overexpression screen in S. cerevisiae. PLoS Genet, 4(7), 2008, e1000120.
6. 6 Bowerman, B., Eaton, B.A., Priess, J.R., Skn-1, a maternally expressed gene required to specify the fate of ventral blastomeres in the early C. elegans embryo. Cell 68:6 (1992), 1061–1075.
7. 7 Murakami, S., Motohashi, H., Roles of Nrf2 in cell proliferation and differentiation. Free Radic Biol Med 88:Pt B (2015), 168–178.
8. 8 Skoko, J.J., Wakabayashi, N., Noda, K., Kimura, S., Tobita, K., Shigemura, N., et al. Loss of Nrf2 in mice evokes a congenital intrahepatic shunt that alters hepatic oxygen and protein expression gradients and toxicity. Toxicol Sci Off J Soc Toxicol 141:1 (2014), 112–119.
9. 9 Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:7484 (2014), 495–501.
10. 10 Kobayashi, A., Kang, M.I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:16 (2004), 7130–7139.
11. 11 Zhang, D.D., Lo, S.C., Cross, J.V., Templeton, D.J., Hannink, M., Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24:24 (2004), 10941–10953.
12. 12 Zhang, D.D., Hannink, M., Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol 23:22 (2003), 8137–8151.
13. 13 Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N., Katoh, Y., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99:18 (2002), 11908–11913.
14. 14 Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through chip-seq profiling and network analysis. Nucleic Acids Res 38:17 (2010), 5718–5734.
15. 15 Chorley, B.N., Campbell, M.R., Wang, X., Karaca, M., Sambandan, D., Bangura, F., et al. Identification of novel NRF2-regulated genes by ChiP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res 40:15 (2012), 7416–7429.
16. 16 McMahon, M., Lamont, D.J., Beattie, K.A., Hayes, J.D., Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc Natl Acad Sci U S A 107:44 (2010), 18838–18843.
17. 17 Takaya, K., Suzuki, T., Motohashi, H., Onodera, K., Satomi, S., Kensler, T.W., et al. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53:4 (2012), 817–827.
18. 18 Hast, B.E., Goldfarb, D., Mulvaney, K.M., Hast, M.A., Siesser, P.F., Yan, F., et al. Proteomic analysis of ubiquitin ligase Keap1 reveals associated proteins that inhibit Nrf2 ubiquitination. Cancer Res 73:7 (2013), 2199–2210.
19. 19 Chen, W., Sun, Z., Wang, X.J., Jiang, T., Huang, Z., Fang, D., et al. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34:6 (2009), 663–673.
20. 20 Lau, A., Wang, X.J., Zhao, F., Villeneuve, N.F., Wu, T., Jiang, T., et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 30:13 (2010), 3275–3285.
21. 21 Rada, P., Rojo, A.I., Chowdhry, S., McMahon, M., Hayes, J.D., Cuadrado, A., Scf/{beta}-Trcp promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31:6 (2011), 1121–1133.
22. 22 Wu, T., Zhao, F., Gao, B., Tan, C., Yagishita, N., Nakajima, T., et al. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev 28:7 (2014), 708–722.
23. 23 DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:7354 (2011), 106–109.
24. 24 Tao, S., Wang, S., Moghaddam, S.J., Ooi, A., Chapman, E., Wong, P.K., et al. Oncogenic KRAS confers chemoresistance by upregulating Nrf2. Cancer Res 74:24 (2014), 7430–7441.
25. 25 Ramos-Gomez, M., Kwak, M.K., Dolan, P.M., Itoh, K., Yamamoto, M., Talalay, P., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98:6 (2001), 3410–3415.
26. 26 Pearson, K.J., Lewis, K.N., Price, N.L., Chang, J.W., Perez, E., Cascajo, M.V., et al. Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A 105:7 (2008), 2325–2330.
27. 27 Padmanabhan, B., Tong, K.I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21:5 (2006), 689–700.
28. 28 Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., et al. Dysfunctional Keap1-Nrf2 interaction in non-small-cell lung cancer. PLoS Med, 3(10), 2006, e420.
29. 29 Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27:20 (2013), 2179–2191.
30. 30 Sandhu, I.S., Maksim, N.J., Amouzougan, E.A., Gallion, B.W., Raviele, A.L., Ooi, A., Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). Biochem Soc Trans 43:4 (2015), 650–656.
31. 31 Ooi, A., Wong, J.C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20:4 (2011), 511–523.
32. 32 Marhenke, S., Lamle, J., Buitrago-Molina, L.E., Canon, J.M., Geffers, R., Finegold, M., et al. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology 48:2 (2008), 487–496.
33. 33 Ooi, A., Dykema, K., Ansari, A., Petillo, D., Snider, J., Kahnoski, R., et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 73:7 (2013), 2044–2051.
34. 34 Cancer Genome Atlas Research N, Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374:2 (2016), 135–145.
35. 35 Haake, S.M., Weyandt, J.D., Rathmell, W.K., Insights into the genetic basis of the renal cell carcinomas from the cancer genome atlas. Mol Cancer Res, 2016.
36. 36 Cancer Genome Atlas Research N, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511:7511 (2014), 543–550.
37. 37 Cancer Genome Atlas Research N, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:7492 (2014), 315–322.
38. 38 Cancer Genome Atlas Research N, Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:7417 (2012), 519–525.
39. 39 Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47:5 (2015), 505–511.
40. 40 Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44:6 (2012), 694–698.
41. 41 Wang, R., An, J., Ji, F., Jiao, H., Sun, H., Zhou, D., Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 373:1 (2008), 151–154.
42. 42 Hanada, N., Takahata, T., Zhou, Q., Ye, X., Sun, R., Itoh, J., et al. Methylation of the Keap1 gene promoter region in human colorectal cancer. BMC Cancer, 12, 2012, 66.
43. 43 Barbano, R., Muscarella, L.A., Pasculli, B., Valori, V.M., Fontana, A., Coco, M., et al. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 8:1 (2013), 105–112.
44. 44 Muscarella, L.A., Barbano, R., D'Angelo, V., Copetti, M., Coco, M., Balsamo, T., et al. Regulation of Keap1 expression by promoter methylation in malignant gliomas and association with patient's outcome. Epigenetics 6:3 (2011), 317–325.
45. 45 Kovac, M., Navas, C., Horswell, S., Salm, M., Bardella, C., Rowan, A., et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat Commun, 6, 2015, 6336.
46. 46 Umemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., et al. P62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29:6 (2016), 935–948.
47. 47 Solis, L.M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N.C., Moran, C.A., et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 16:14 (2010), 3743–3753.
48. 48 Satoh, H., Moriguchi, T., Takai, J., Ebina, M., Yamamoto, M., Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 73:13 (2013), 4158–4168.
49. 49 Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15:10 (2009), 3423–3432.
50. 50 Fukumoto, S., Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers’ non-small cell lung carcinomas. Clin Cancer Res 11:5 (2005), 1776–1785.
51. 51 Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:2 (1997), 313–322.
52. 52 Li, J., Stein, T.D., Johnson, J.A., Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. Physiol Genomics 18:3 (2004), 261–272.
53. 53 Cho, H.Y., Reddy, S.P., Debiase, A., Yamamoto, M., Kleeberger, S.R., Gene expression profiling of Nrf2-mediated protection against oxidative injury. Free Radic Biol Med 38:3 (2005), 325–343.
54. 54 Agyeman, A.S., Chaerkady, R., Shaw, P.G., Davidson, N.E., Visvanathan, K., Pandey, A., et al. Transcriptomic and proteomic profiling of Keap1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat 132:1 (2012), 175–187.
55. 55 Gebel, S., Diehl, S., Pype, J., Friedrichs, B., Weiler, H., Schuller, J., et al. The transcriptome of Nrf2−/− mice provides evidence for impaired cell cycle progression in the development of cigarette smoke-induced emphysematous changes. Toxicol Sci Off J Soc Toxicol 115:1 (2010), 238–252.
56. 56 Mitsuishi, Y., Motohashi, H., Yamamoto, M., The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol, 2, 2012.
57. 57 Wakabayashi, N., Shin, S., Slocum, S.L., Agoston, E.S., Wakabayashi, J., Kwak, M.K., et al. Regulation of Notch1 signaling by Nrf2: implications for tissue regeneration. Sci Signal, 3(130), 2010, ra52.
58. 58 Kim, J.H., Thimmulappa, R.K., Kumar, V., Cui, W., Kumar, S., Kombairaju, P., et al. Nrf2-mediated notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124:2 (2014), 730–741.
59. 59 Paul, M.K., Bisht, B., Darmawan, D.O., Chiou, R., Ha, V.L., Wallace, W.D., et al. Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent notch signaling. Cell Stem Cell 15:2 (2014), 199–214.
60. 60 Pi, J., Leung, L., Xue, P., Wang, W., Hou, Y., Liu, D., et al. Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. J Biol Chem 285:12 (2010), 9292–9300.
61. 61 Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22:1 (2012), 66–79.
62. 62 Barfeld, S.J., Mills, I.G., Mapping protein-DNA interactions using chip-exo and illumina-based sequencing. Methods Mol Biol 1443 (2016), 119–137.
63. 63 Rhee, H.S., Pugh, B.F., Chip-exo method for identifying genomic location of DNA-binding proteins with near-single-nucleotide accuracy. [Edited by Frederick M Ausubel [et al]] Curr Protoc Mol Biol, 2012 Chapter 21(Unit 21.24).
64. 64 He, Q., Johnston, J., Zeitlinger, J., Chip-nexus enables improved detection of in vivo transcription factor binding footprints. Nat Biotechnol 33:4 (2015), 395–401.
65. 65 Soylu, I., Marino, S.M., Cy-preds: an algorithm and a web service for the analysis and prediction of cysteine reactivity. Proteins 84:2 (2016), 278–291.